@article{916cbfa854c7419fb28cc7f78cc99b8d,
title = "Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal",
keywords = "1ST-LINE TREATMENT, ENDOCRINE THERAPY, LETROZOLE, BEVACIZUMAB, PALBOCICLIB, UTILITY",
author = "Buyukkaramikli, {Nasuh C.} and {de Groot}, Saskia and Rob Riemsma and Debra Fayter and Nigel Armstrong and Piet Portegijs and Steven Duffy and Jos Kleijnen and Al, {Maiwenn J.}",
year = "2019",
month = feb,
doi = "10.1007/s40273-018-0708-4",
language = "English",
volume = "37",
pages = "141--153",
journal = "Pharmacoeconomics",
issn = "1170-7690",
publisher = "Adis International Ltd",
number = "2",
}